Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 3

The therapeutic effects of Rho-ROCK inhibitors on CNS disorders

Authors Kubo T, Yamaguchi A, Iwata N, Yamashita T

Published 6 June 2008 Volume 2008:4(3) Pages 605—615

DOI https://doi.org/10.2147/TCRM.S2907

Takekazu Kubo1, Atsushi Yamaguchi1, Nobuyoshi Iwata2, Toshihide Yamashita1,3

1Department of Neurobiology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan; 2Information Institute for Medical Research Ltd.; 3Department of Molecular Neuroscience, Graduate School of Medicine, Osaka University 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan

Abstract: Rho-kinase (ROCK) is a serine/threonine kinase and one of the major downstream effectors of the small GTPase Rho. The Rho-ROCK pathway is involved in many aspects of neuronal functions including neurite outgrowth and retraction. The Rho-ROCK pathway becomes an attractive target for the development of drugs for treating central nervous system (CNS) disorders, since it has been recently revealed that this pathway is closely related to the pathogenesis of several CNS disorders such as spinal cord injuries, stroke, and Alzheimer’s disease (AD). In the adult CNS, injured axons regenerate poorly due to the presence of myelin-associated axonal growth inhibitors such as myelin-associated glycoprotein (MAG), Nogo, oligodendrocyte-myelin glycoprotein (OMgp), and the recently identified repulsive guidance molecule (RGM). The effects of these inhibitors are reversed by blockade of the Rho-ROCK pathway in vitro, and the inhibition of this pathway promotes axonal regeneration and functional recovery in the injured CNS in vivo. In addition, the therapeutic effects of the Rho-ROCK inhibitors have been demonstrated in animal models of stroke. In this review, we summarize the involvement of the Rho-ROCK pathway in CNS disorders such as spinal cord injuries, stroke, and AD and also discuss the potential of Rho-ROCK inhibitors in the treatment of human CNS disorders.

Keywords: neuron, Rho, Rho-kinase, axonal regeneration, central nervous system disorder

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Toxic anterior segment syndrome after uncomplicated cataract surgery possibly associated with intracamaral use of cefuroxime

Çakır B, Celik E, Aksoy NÖ, Bursalı Ö, Uçak T, Bozkurt E, Alagoz G

Clinical Ophthalmology 2015, 9:493-497

Published Date: 17 March 2015

Perindopril for improving cardiovascular events

DiNicolantonio JJ, O’Keefe JH

Vascular Health and Risk Management 2014, 10:539-548

Published Date: 30 August 2014

Titanium dioxide induces apoptotic cell death through reactive oxygen species-mediated Fas upregulation and Bax activation

Yoo KC, Yoon CH, Kwon DW, Hyun KH, Woo SJ, Kim RK, Lim EJ, Suh YJ, Kim MJ, Yoon TH, Lee SJ

International Journal of Nanomedicine 2012, 7:1203-1214

Published Date: 5 March 2012

Survival of women with breast cancer in central and northern Denmark, 1998–2009

Lietzen LW, Sørensen GV, Ording AG, Garne JP, Christiansen P, Nørgaard M, Jacobsen J

Clinical Epidemiology 2011, 3:35-40

Published Date: 21 July 2011

Survival of invasive bladder cancer patients, 1998–2009; a central and northern Denmark population-based cohort study

Lund L, Erichsen R, Nørgaard M, Larsen EH, Borre M, Jacobsen J

Clinical Epidemiology 2011, 3:47-51

Published Date: 20 July 2011

Treatment strategies in mucous membrane pemphigoid

Ann G Neff, Matthew Turner, Diya F Mutasim

Therapeutics and Clinical Risk Management 2008, 4:617-626

Published Date: 6 June 2008